GLP-1 Peptide Atlas, by Delfa

UnknownPhase NA

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

Efficacy and Durability of Glucagon Like Peptide 1 Receptor Agonists (GLP-1 RA)/Thiazolidinedione Versus Basal Bolus Insulin Therapy in Poorly Controlled Type 2 Diabetic Patients (T2DM) Patients on Sulfonylurea Plus Metformin

Lead sponsor

Dr. Muhammad Abdulghani

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

410

estimated

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c ≥7.5%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02887625

Org study IDNPRP 5-273-3-079

Timeline

Milestones

Study first posted2016-09-02estimated

Last update posted2016-09-02estimated

Study start2015-02 (month precision)

Primary completion2017-05estimated (month precision)

Study completion2017-05estimated (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•T2DM poorly controlled (HbA1c >7.5%) on metformin (>1700 mg/day) plus sulfonylurea

Exclusion criteria

•type 1 diabetes (T1DM) patients receiving therapy with pioglitazone, GLP-1 RA and insulin abnormal kidney, liver or heart function patients with malignancy

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

change in body weight

Time frame:3 years

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

3 endpoints

Primary/protocol endpoint

HbA1c

Time frame:3 years

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

percentage of patients who achieve HbA1c <7.0% and <6.5% at 1 year and at 3 years

Time frame:3 years

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

change in the FPG

Time frame:3 years

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

hypoglycemia rate

Time frame:3 years

event count, event

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.
Diabetes care2017 Mar (month)PMID28096223doi:10.2337/dc16-1738via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.